Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN5678 with or without Cemiplimab in mCRPC and ccRCC
NCT03972657Phase 2Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2019
- Primary completion
- Nov 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of nezastomig in metastatic castration-resistant prostate cancer (mCRPC), clear cell renal cell carcinoma (ccRCC), sponsored by Regeneron Pharmaceuticals. Started Aug 2019; status: recruiting.
02
Drugs
nezastomig
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT03972657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03972657.